Literature DB >> 10030779

Impact of rifampin on serum amiodarone concentrations in a patient with congenital heart disease.

D G Zarembski1, S A Fischer, P A Santucci, M T Porter, M R Costanzo, R G Trohman.   

Abstract

A 33-year-old woman with congenital heart disease and atrial and ventricular arrhythmias, managed over the long term with an implantable cardioverter defibrillator, epicardial pacing system, and amiodarone, experienced an increase in palpitations and a shock from her defibrillator. Evaluation revealed decreases in amiodarone and desethylamiodarone serum concentrations from previous levels. Rifampin had been added to her therapy 5 weeks earlier. Increases in amiodarone and desethylamiodarone concentrations were observed after an increase in the amiodarone dosage and discontinuation of rifampin. The time course suggested that the addition of rifampin led to reductions in serum concentrations of both the drug and metabolite.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10030779     DOI: 10.1592/phco.19.3.249.30929

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Through the looking glass: reminiscence from a pediatrician-come-lately.

Authors:  Richard G Trohman
Journal:  Pediatr Cardiol       Date:  2008-08-14       Impact factor: 1.655

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Tuberculosis and pharmacological interactions: A narrative review.

Authors:  Niccolò Riccardi; Diana Canetti; Paola Rodari; Giorgio Besozzi; Laura Saderi; Marco Dettori; Luigi R Codecasa; Giovanni Sotgiu
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.